Abstract. Glutamate is the dominant excitatory neurotransmitter in a large number of physiological processes including neuroendocrine regulation. Some pharmacological studies have shown that different subtypes of glutamate receptor, such as the N-methyl-D-aspartic acid (NMDA) and α-amino-3-hydroxy-5-methy-4-isoxazolepropionic acid (AMPA) receptors, are involved in stress-induced adrenocorticotropin (ACTH) and prolactin secretion. However, the roles of the respective glutamate receptors and the mechanism of ACTH and prolactin secretion during stress via these receptors have not been investigated in detail. In the present study, we evaluated the role of AMPA-type glutamate receptor in ACTH and prolactin regulation under restraint stress in adult male rats. Male rats pretreated with a selective AMPA receptor antagonist, 2, 3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX; 50 µg), through a lateral ventricle cannula were stressed by immobilization. Administration of NBQX inhibited ACTH and prolactin secretion in response to restraint stress. However, NBQX had no significant effects on the activity of tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine biosynthesis, as measured by the accumulation of 3, 4-dihydroxyphenylalanine (DOPA). In addition, administration of NBQX suppressed stress-induced prolactin secretion in the male rats pretreated with α-MT, an inhibitor of dopamine synthesis, and infused with dopamine solution (2.5 µg/200 µl/10 min). These results indicated that the effects of NBQX on prolactin secretion might be mediated by non-dopamine mechanisms. The contents of corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) in the median eminence (ME) of the male rats decreased during restraint stress; however, the fluctuations in CRH and AVP were eliminated by NBQX administration. These results suggest that stress-induced ACTH and prolactin release mediated by neurotransmission via AMPA receptors might be partly attributable to hypophysiotropic regulatory factors in the hypothalamus. Key words: Adrenocorticotropin (ACTH), α-Amino-3-hydroxy-5-methy-4-isoxazolepropionic acid (AMPA), Prolactin, Rat, Stress (J. Reprod. Dev. 53: [545][546][547][548][549][550][551][552][553][554] 2007) he excitatory amino acid glutamate is the primary mediator of excitatory synaptic transmission in the central nervous system [1, 2] .
Glutamate binds different receptor subtypes, such as N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainate receptors [3, 4] . These receptors are localized in several hypothalamic nuclei, suggesting that glutamate mediates various neuroendocrine functions [5] [6] [7] [8] [9] [10] [11] [12] [13] .
Several pharmacological studies have shown that glutamate is a potent modulator of adrenocorticotropin (ACTH) and prolactin secretion [14] [15] [16] [17] . Simultaneous blockade of NMDA and AMPA/kainate receptors results in mild inhibition of immobilization-induced ACTH release [18] . Jezova et al. [19] reported that ACTH secretion in response to immobilization stress was inhibited by p r e t r e a t m e n t w i t h a c e n t r a l l y a c t i n g noncompetitive NMDA antagonist MK-801, but not by a competitive NMDA receptor antagonist, CPP. Zelena et al. [18] also described that blockade of the combination of the NMDA and AMPA/kainate subtypes of glutamate receptor by MK-801 and GYKI 52466 prevented the rise in plasma prolactin in response to footshock stress in male rats. These reports indicated that the NMDA and AMPA receptors play important roles in regulation of ACTH and prolactin release in response to stress. Evidence showing that the NMDA and AMPA receptor mRNA levels change in the various brain areas of the rats after immobilization might also support the contribution of these receptors to neuroendocrine function in response to stress [20] . However, the roles of glutamate receptors in relation to the hypohysiotropic factors regulating secretion of ACTH and prolactin have not been investigated in detail. The roles of the NMDA, AMPA and kainate receptors in ACTH and prolactin secretion are also unclear, especially in regard to the physiological significance of the AMPA and kainate receptors in regulation of these two pituitary hormones under stress conditions.
The aim of the present study was to clarify the role of AMPA-type glutamate receptor in ACTH and prolactin secretion in rats under immobilization. We examined the secretion of ACTH and prolactin induced by restraint stress in adult male rats pretreated with intracerebroventricular (i.c.v.) administration of NBQX, a selective AMPA receptor antagonist. The effects of NBQX on the contents of corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) and on the activity of tyrosine hydroxyrase (TH) in the median eminence (ME) were also examined.
Materials and Methods

Animals
Adult male rats of the Wistar Imamichi strain (2-3 months of age) were used. They were kept in a room with controlled illumination (lights on from 0500 h to 1900 h) and temperature (25 ± 2 C) and access to food and water ad libitum. Animals weighing 300-350 g were caged individually. The experimental protocol was approved in accordance with the Guide for the Care and Use of Laboratory Animals prepared by the Tokyo University of Agriculture and Technology.
Drugs
S p e c i f i c A M P A r e c e p t o r a n t a g o n is t 2 ,3 -d i h y d r o x y -6 -n i t r o -7 -s u l f a m o y l -b e n z o ( f ) quinoxaline (NBQX) [21] was purchased from Sigma-Aldrich (St. Louis, MO, USA) and dissolved initially in a few drops of dimethylsulfoxide. Thereafter, the drug was dissolved in artificial c er e br al sp i na l fl uid u p to th e w o rk in g concentration (50 µg/10 µl). The dose of NBQX chosen (50 µg) was the highest dose used in previous reports examining i.c.v. administration of NBQX [22] . We also confirmed that treatment with NBQX at this dose did not affect the basal secretion o f A C T H a n d P R L o r i n d u c e b e h a v i o r a l abnormalities. The artificial cerebral spinal fluid consisted of a modified Krebs-Ringer phosphate solution containing 123 mM NaCl, 10.2 mM Na 2 HPO 4 , 4.8 mM KCl, 1.8 mM NaH 2 PO 4 , 1.2 mM MgSO 4 and 0.78 mM CaCl 2 adjusted to pH 7.4 [23] .
Surgical procedures R a t s w e r e a n e s t h e t i z e d w i t h s o d i u m pentobarbital (35 mg/kg BW, i.p.), and a 21-gauge stainless steel cannula (Plastics One, Roanoke, VA, USA) was placed chronically into the right lateral ventricle of the brain using a Kopf stereotaxic instrument [23] . The cannula was implanted 1.0 mm posterior, 1.5 mm to the right of the bregma, and 3.7 mm below the dorsal surface of the brain according to the atlas of Paxinos and Watson [24] . The apparatus was cemented into place using dental acrylic adhered with 3 screws in the skull serving as the foundation. A 26-gauge dummy cannula extending 4.0 mm below the tip of the outer cannula was inserted until the day of the experiment. Recovery time from the stereotaxic surgery to the experiment was at least one week, and the time from jugular cannulation to the experiment was 48 h.
Immobilization stress
To investigate ACTH and prolactin secretion in response to restraint stress, animals were stressed by immobilization in a small disposable restrainer (DecapiCone, Braintree Scientific, Braintree, MA, USA) for 15 or 60 min [25] . Forty-eight hours before the stress experiment, a silastic cannula was inserted into the right atrium via the external jugular vein of each rat in order to draw blood samples. Before and during stress exposure, blood samples (700 µl) were withdrawn through the atrial cannula and replaced with an equal volume of heparinized saline. 
Administration of NBQX
ACTH and prolactin secretion in response to restraint stress in rats pretreated with NBQX
To evaluate the physiological significance of AMPA receptors for ACTH and prolactin secretion in response to restraint stress, the plasma concentrations of ACTH and prolactin during restraint stress were measured in male rats pretreated with NBQX. The blood samples (700 µl)
for plasma ACTH and prolactin determinations were drawn from jugular cannulas at 30 min, 15 min and just (0 min) before the onset of stress exposure and at 7.5, 15, 30 and 60 min after stress exposure.
CRH and AVP contents in the ME of rats pretreated with NBQX
To clarify the effect of NBQX on the regulation of ACTH secretion, the contents of CRH and AVP in the ME were examined just before and 15 min after the onset of restraint stress in rats pretreated with NBQX. The ME was dissected with a pair of fine scissors, homogenized in 150 µl 0.01N perchloric acid, and centrifuged at 10,000 g for 30 min. The pellet was solubilized in 0.01 N sodium hydroxide and analyzed for protein content by the method of Bradford [26] .
TH activity after restraint stress in rats pretreated with NBQX
To evaluate whether the effects of NBQX on prolactin release are mediated by dopaminergic neurons in stressed rats, the activity of TH in the ME was examined in rats pretreated with NBQX. M a l e r a t s w er e i n je c t ed w i t h m-hy d r o x ybenzylhydrazine dihydrochloride (NSD-1015, 25 mg/kg, i.v.; Sigma), an L-aromatic amino acid decarboxylase inhibitor, just before the onset of restraint stress. Rats were euthanized by decapitation 15 min after the onset of restraint stress. The ME was dissected, homogenized, and centrifuged. The content of 3,4-dihydroxyphenylalanie (DOPA) in the supernatant was determined by High Performance Liquid Chromotography (HPLC) with electrochemical detection [27] .
Effects of NBQX on prolactin secretion in response to restraint stress in rats treated to deplete endogenous dopamine
To examine whether the effects of NBQX on p r o l a c t i n s e c r e t i o n a r e m e d i a t ed b y n o ndopaminergic systems, an experimental model was prepared that eliminated the action of endogenous dopamine. Endogenous dopamine was depleted 30 min before the onset of restraint stress by injection of 50 mg/kg of α-methyl-DL-p-tyrosine methyl ester (α-MT; Sigma) dissolved in saline through the jugular cannula. This dose was chosen based on a previous report demonstrating that it caused a rapid and marked reduction 80% in dopamine in the portal blood [28] . In order to reduce plasma prolactin to basal level, dopamine solution (12.5 µg/ml) was infused through the jugular cannula 
Radioimmunoassay (RIA)
Plasma concentrations of prolactin were measured using NIDDK kits (NIH, Bethesda, MD, USA) for rat prolactin. The hormone for iodination was rat prolactin-I-5. The antiserum was used antiprolactin-S-9. Results are expressed in terms of NIDDK rat prolactin-RP-2. The intra-and interassay coefficients of variation for prolactin w e r e 3 . 4 a n d 5 . 2 % , r e s p e c t i v e l y . P l a s m a concentrations of ACTH [29] and the ME contents of CRH [30] were measured by double-antibody RIAs using 125 I-labeled radioligands as described previously. Synthetic rat ACTH 1-39 (Sigma) was used as the reference standard. Antiserum to CRH was kindly provided by Dr. T. Suda (Hirosaki University, Aomori, Japan).
The intra-and inter-assay coefficients of variation were 11.3 and 11.9% for ACTH and 9.5 and 16.4% for CRH, respectively. The AVP content in the ME was measured using a commercial RIA k i t p u r c h a s e d f r o m M i t s u b i s h i C h e m i c a l Corporation (Tokyo, Japan) [31] . The intra-and interassay coefficients of variation for AVP were 6.9 and 11.2%, respectively.
Statistical analyses
All results are expressed as the mean ± SEM. The data for the plasma concentrations of ACTH and prolactin were analyzed using two-way analysis of variance (ANOVA) followed by Fisher's protected least significant difference (PLSD) test. The CRH and AVP contents in the ME were analyzed using one-way ANOVA followed by Fisher's PLSD test; a value of P<0.05 was considered significant.
Results
ACTH and prolactin secretion in response to restraint stress in rats pretreated with NBQX
Rats received i.c.v administration of NBQX or vehicle (artificial cerebral spinal fluid) 15 min before the onset of restraint stress exposure. The plasma concentration of ACTH dramatically increased after the onset of restraint stress and remained high during stress exposure in the control rats, whereas the ACTH response to restraint stress was imperceptible in the NBQX-pretreated rats. Significant differences in ACTH values were found between the NBQX-pretreated and control rats at 7.5, 15, 30 and 60 min after the onset of restraint stress (Fig. 1A) .
The plasma concentration of prolactin increased in the control rats following restraint stress exposure. The peak levels of prolactin were observed at 7.5 min after stress in the control rats. However, there was no change in prolactin secretion in response to restraint stress in the NBQX-pretreated rats. Significant differences in prolactin values were found between the NBQXpretreated and control rats at 7.5, 15 and 30 min after the onset of restraint stress (Fig. 1B) .
CRH and AVP contents in the ME of rats pretreated with NBQX
No significant differences were observed in CRH and AVP in the ME within 15 min before stress exposure (from i.c.v infusion until the onset of restraint stress) in both groups (data not shown). The CRH and AVP contents in the ME significantly decreased in the control rats 15 min after stress exposure compared with those just before the onset of restraint stress ( Fig. 2A and B) . However, no changes were observed for the CRH and AVP contents in the ME during stress in the NBQXpretreated rats ( Fig. 2A and B) .
TH activity after restraint stress in rats pretreated with NBQX
The TH activity in the ME was measured by accumulation of DOPA 15 min after injection of NSD-1015 (25.0 mg/kg, i.v.) and was slightly lower in the NBQX-pretreated rats compared with the control rats. However, there were no statistically significant differences between the groups (Fig. 3) .
Effects of NBQX on prolactin secretion in response to restraint stress in rats treated to deplete endogenous dopamine
The plasma levels of prolactin decreased as a result of dopamine infusion (2.5 µg/200 µl/10 min) and almost completely recovered to the basal level after administration of α-MT (50 mg/kg; Fig. 4) . Additionally, no changes were observed in the plasma prolactin levels of the NBQX-treated rats. Increasing prolactin levels were observed following restraint stress in both groups; however, the peak levels of prolactin were lower in the NBQX-treated rats than in the control rats. Significant differences in prolactin values were found between the NBQXpretreated and control rats at 7.5, 15 and 30 min after the onset of immobilization (Fig. 4) .
Discussion
In the present study, we addressed the questions of whether i.c.v. administration of a selective AMPA-type glutamate receptor antagonist, NBQX, alters ACTH and prolactin secretion in response to restraint stress and whether NBQX-induced changes in ACTH and prolactin secretion are associated with hypophysiotropic regulatory factors.
The plasma concentrations of ACTH increased in response to restraint stress in the control rats, while i.c.v. administration of NBQX resulted in inhibition of ACTH response to restraint stress in the present study. The CRH and AVP contents of the ME decreased within 15 min after stress in the control rats but did not decrease after stress in the NBQXtreated rats. These results indicate that the stressinduced alterations of CRH and AVP in the ME were inhibited by the NBQX treatment. Some evidence has been reported showing that glutamate affected CRH or AVP at the levels of the ME. Saito et al. [32] recently reported that running stress decreased the ME content of AVP and increased in the plasma concentrations of ACTH in male rats, and they suggested that the reduction of the AVP content in the ME might be the result of an increase of AVP release into the portal blood. In the present study, NBQX-induced suppression of ACTH secretion may have been mediated by the inhibition of CRH and AVP release into the portal vein. A previous study showing that glutamate receptors are located in the ME [33] supports our theory about the action site of NBQX in the present study. The AMPA receptor has been found in PVN and SON, which the CRH and AVP neurons are located in [8, 9, 11, 12] . These areas may also be the action sites of glutamate via the AMPA receptor. Previous reports have also mentioned that glutamate and glutamate receptors may play a role in activation of the hypothalamic-pituitary axis (HPA) axis during stress [20, [34] [35] [36] . For instance, AMPA receptor mRNA levels are elevated in the hippocampus and hypothalamus of rats after immobilization stress [20] . Although the receptor of AMPA was not examined in the present study, the density or affinity of the receptor may also change under stress conditions. It has also been reported that immobilization stress enhanced NMDA receptor b i n d i n g i n t h e h y p o t h a l a m u s 2 4 h a f t e r immobilization and that this effect was reproduced by exogenous administration of stress levels of corticosteroid [36] . These reports also support our results in the present study. However, some evidence has been reported showing that glutamate affected CRH or AVP at the levels of the ME. In the present study, we confirmed that glutamate neurotransmission via the AMPA receptor was involved in activation of the HPA axis during restraint stress. This suggests that the AMPA receptor regulates ACTH secretion, probably mediated by CRH and AVP release at the level of the ME, in addition to PVN and SON. P<0.05, compared with the value for the respective controls (two-way ANOVA followed by Fisher's PLSD test).
In the present study, the plasma concentrations of prolactin in the control male rats increased in r e s p o n s e t o r e s t r a i n t s t r e s s , w h i l e i . c . v . administration of NBQX inhibited prolactin secretion in response to restraint stress. NBQX treatment resulted in no significant change in the activity of the enzyme for dopamine synthesis, TH in the ME 15 min after the onset of restraint stress. T h e s e r e s u l t s s u g g e s t t h a t d o p a m i n e r g i c neurotransmission in the ME is not important for the effects of AMPA receptor antagonist on prolactin secretion. Although we did not confirm the effects of NBQX on dopamine or DOPAC in the ME in the present study, previous reports suggest that systemic administration of NBQX increases the primary dopamine metabolite DOPAC in the ME [37] and that the distribution of AMPA receptorimmunoreactive neurons overlaps that of THimmunoreactive neurons in the arcuate nucleus [38] . The main difference between our results and one of the previous reports might be the route of administration of NBQX. In the present study, the i.c.v. route was chosen to examine the effects of NBQX within the central nervous system (CNS), while systemic injection was chosen in the previous report [37] . Glutamate receptor immunostaining in the anterior pituitary has also been reported [39, 40] , and glutamate has been reported to enhance prolactin release directly from perifused anterior pituitary cells in vitro [41] , suggesting that direct modulation by glutamate in the anterior pituitary is also possible. Systemic injection of NBQX might affect dopamine neuron in the ME thorough two ways: through the direct action of NBQX in the ME and through indirect action mediated by NBQXinduced prolactin release at the pituitary level. Our results in the present study reflect the function of the AMPA receptor within the CNS and not at the pituitary level.
Dopamine is a prolactin-inhibiting factor that is thought to be a dominant modulator of prolactin secretion [42] [43] [44] [45] ; however, it is generally accepted that prolactin secretion is mediated by other neuropeptides acting as prolactin-releasing factors [46] in addition to the inhibitory dopaminergic tone. To examine whether the effects of NBQX on prolactin secretion are mediated by non-dopamine mechanisms, an experimental model that excluded the influence of endogenous dopamine was d e s i g n e d i n t h i s s t u d y . F o r d e p l e t i o n o f endogenous dopamine, adult male rats were i n j e c t e d ( i . p . ) w i t h α -M T ( 5 0 m g / k g ) , a catecholamine synthesis inhibitor, and infused with dopamine solution (2.5 mg/200 µl/10 min) through a j u g u l a r c a n n u l a t o r e t a i n t h e p l a s m a concentrations of prolactin at the physiological level. As a result of using these model rats, administration of NBQX suppressed stress-induced prolactin secretion in the male rats, which had little endogenous dopamine, indicating that NBQXinduced suppression of prolactin secretion might be mediated by non-dopamine mechanisms and might be able attribute to modification of prolactinreleasing factors.
The candidates for prolactin-releasing factors include neuropeptides such as thyrotrophinreleasing hormone (TRH) [47] [48] [49] , vasoactive intestinal polypeptide (VIP) [43, 45, 50] , AVP [51] [52] [53] , oxytocin [54] [55] [56] , and prolactin-releasing peptide [57] . The AMPA receptor is present in the paraventricular and supraoptic nuclei, which is where the cell bodies of these prolactin-releasing factors are located [8] [9] [10] [11] [12] . In the present study, the effects of NBQX on primary prolactin-releasing factors such as TRH and VIP were not examined. However, considering that AVP is a prolactinreleasing factors and that its content in the ME did not decrease after stress in the NBQX-treated rats, NBQX-induced suppression of prolactin release can, in part, be attributed to prolactin-releasing factors [48, 51] .
In a previous report on the potential importance of the glutamate receptor in stress-induced ACTH and prolactin release, Zelena et al. [18] reported that simultaneous blockade of two glutamate receptor subtypes (NMDA and AMPA) resulted in mild inhibition of immobilization-induced ACTH release and prevented the rise in plasma prolactin in response to footshock stress. These results indicate that both the NMDA and AMPA receptors play an important role in stress-induced ACTH and prolactin release. On the other hand, it has been reported that secretion of ACTH in response to immobilization stress is inhibited by pretreatment with a high dose of MK-801 (blockade of NMDA receptor alone) [19] . In the present study, we demonstrated that administration of an antagonist of the AMPA receptor eliminated stress-induced ACTH and prolactin release.
Blockade of only AMPA receptor via the i.c.v. route may be one of the reasons for the clear inhibition of ACTH and prolactin secretion in the present study. Systemic injection was chosen for administration of each antagonist in some previous reports [18, 19] but this type of administration could result in peripheral response in addition to response within the CNS. In the present study, the dose of NBQX was relatively higher than in previous reports, but the plasma concentrations of ACTH and prolactin were unchanged before the onset of stress, suggesting that the pharmacological effects of NBQX and invasive effects of i.c.v. administration were eliminated.
In summary, i.c.v. administration of NBQX inhibited ACTH and prolactin secretion in response to restraint stress. These results indicate that neurotransmission via the AMPA receptor plays important roles in ACTH and prolactin secretion in response to restraint stress. NBQX had no significant effects on tuberoinfundibular dopamine neuron activity, and it suppressed stress-induced prolactin secretion in male rats pretreated with α-M T a nd i n f u s ed w i t h d op a m i n e s o l u t i o n , suggesting that the effects of NBQX on prolactin secretion may be mediated by non-dopamine mechanisms. NBQX also blocked the decreases of CRH and AVP contents in the ME after restraint stress. Glutamate neurotransmission via AMPA receptors is also involved in the stress-induced CRH and AVP responses in the hypothalamus, and these or other hormones or neurotransmitters may play roles as hypophysiotropic factors for ACTH and prolactin release in response to stress.
